This suggested that LCOR could be considered as a new clinical biomarker for the diagnosis and prognosis of ccRCC, offering an opportunity for the research of novel drugs targeting LCOR-RUNX1-PLCL1. This evidence concerns the gene RUNX1 and nonpapillary renal cell carcinoma.